# SGLT2i Effect on PTDM Development and Kidney Allograft Function in Non-diabetic Kidney Transplant Recipients: A Randomized, Doubleblind, Placebo Controlled, National Multicenter Trial

> **NCT07682350** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Odense University Hospital** · enrollment: 184 (estimated)

## Conditions studied

- Kidney Transplant Recipient
- Sodium Glucose Co-Transporter 2 Inhibitors
- Non-Diabetic Patients
- Randomized Controlled Trial (RCT)
- Placebo Control Design
- Post Transplant Diabetes Mellitus

## Interventions

- **DRUG:** SGLT2i
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07682350
- **Lead sponsor:** Odense University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-01
- **Primary completion:** 2029-09-01
- **Final completion:** 2029-10-01
- **Target enrollment:** 184 (ESTIMATED)
- **Last updated:** 2026-07-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07682350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07682350, "SGLT2i Effect on PTDM Development and Kidney Allograft Function in Non-diabetic Kidney Transplant Recipients: A Randomized, Doubleblind, Placebo Controlled, National Multicenter Trial". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07682350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*